Lion's Mane Research: What We Know and What We Don't

The evidence that Lion's Mane improves focus in healthy adults is thin, and much thinner than the marketing implies. A 2025 systematic review registered with PROSPERO catalogued the complete human literature on the mushroom and found five randomised controlled trials, three pilot trials, one cohort study and one case report; its pooled cognitive signal came from just one RCT and one pilot, and amounted to 1.17 points on the MMSE, a 30-point cognitive screening test. The single most-cited positive trial studied 30 people who all had diagnosed mild cognitive impairment, at 3 grams a day, and the benefit had disappeared four weeks after they stopped taking it. The most recent trial in healthy younger adults, a crossover study in 18 people, found no significant effect on global cognitive function or mood.

Explaining the Topic

Lion's Mane is the common name for Hericium erinaceus, an edible mushroom. It is sold widely as a cognitive supplement, which means the interesting question is not what it is but what has actually been tested in people.

Some vocabulary, because the distinctions below carry most of the weight.

A randomised controlled trial, or RCT, assigns people at random to the substance or a placebo. Randomisation is what makes the comparison meaningful.

A pilot study is a small, preliminary trial run to see whether a bigger trial is feasible and worth doing. Pilots are not designed to answer whether something works. They are designed to find out whether the question can be asked properly. Treating a pilot result as a finding is one of the most common misreadings in supplement marketing.

A crossover trial gives every participant both the substance and the placebo at different times, so each person acts as their own comparison. It is efficient with small numbers.

The MMSE, or Mini-Mental State Examination, is a 30-point screening instrument used mainly to detect cognitive impairment. It is a clinical screening tool, not a measure of how sharp a healthy person feels at their desk.

Statistical significance, usually reported as a p-value, is the conventional threshold for treating a result as unlikely to be chance. A p-value of 0.05 or below is the usual line. A result at p = 0.051 sits just on the wrong side of it, and it is a trend, not a finding.

What the Evidence Actually Says

What is reasonably supported

Here is the entire human trial literature we have verified, with its real numbers.

The 2025 systematic review by Menon and colleagues, registered with PROSPERO as CRD42024571250, put a boundary around all of it: five randomised controlled trials, three pilot trials, one cohort study, one case report. That is the whole human evidence base for a mushroom sold on cognition. And its pooled cognitive signal was drawn from one RCT and one pilot, amounting to 1.17 points on the 30-point MMSE.

So what is reasonably supported? Something narrow. In a clinical population with diagnosed mild cognitive impairment, at 3 grams a day, over 16 weeks, one trial of 30 people found improvement on cognitive scores while people were taking it. That is a real result and it is worth reporting accurately. It is also a small trial, in a diagnosed population, at a gram-level dose, and the authors reported that the scores decreased significantly four weeks after the supplement was stopped. The benefit did not persist.

Docherty and colleagues, 2023, is the one acute signal in healthy people, and it is a pilot: 41 participants at 1.8 g, with faster Stroop performance at 60 minutes at p = 0.005. The same paper is unusually careful about its own limits. Stress reduction at 28 days reached only p = 0.051, which is a trend and not significance. The authors wrote that "null and limited negative findings were also observed" and said the results should be "interpreted with caution."

What is uncertain

Almost everything that matters to a healthy adult buying a supplement.

Nobody knows the effective dose in healthy people. The trials that reported benefit used 3 g and 1.8 g. The pilot in Alzheimer's patients used 1,050 mg of a specific mycelium preparation over 49 weeks. Those are three different doses of three different things in three different populations.

Extract type differs across the literature and none have been compared head to head. Mori 2009 used the mushroom itself, Li 2020 used an erinacine A-enriched mycelium, and Surendran 2025 used a standardised 10:1 extract. These are not interchangeable inputs, and no trial has tested one against another, so there is no basis for saying which form, if any, matters.

The samples are far too small to establish a safety profile. Thirty people, 41 people, 18 people. The Li 2020 pilot recorded four dropouts reporting abdominal discomfort, nausea or rash, which is the kind of signal that needs a much larger trial to interpret properly rather than to dismiss.

And no published trial has tested a multi-mushroom combination at all. Every study above tested Lion's Mane on its own.

What is often overstated in marketing

The word "nootropic", applied confidently. The evidence base is five RCTs, three pilots, one cohort study and one case report, with a pooled signal of 1.17 MMSE points from two studies. That does not support a confident cognitive claim in healthy adults, and we do not make one.

The habit of citing Mori 2009 without its conditions. It gets quoted as "clinically shown to improve cognition" with the sample size, the diagnosed population, the 3-gram dose and the reversal after stopping all left out. All four of those facts change what the trial means.

The habit of citing narrative reviews as if they were evidence of effect. A narrative review is an author's summary of a field. It does not pool data and it does not test anything. There is a 2025 narrative review on Lion's Mane in Nutrients, and it appears in our further reading list for that reason, not in our evidence.

The Most Informative Point in the Whole Literature

Surendran 2025 deserves its own heading. It is a crossover RCT in 18 healthy younger adults using 3 g of a standardised 10:1 extract, and it found "no significant effect ... for composite measures of global cognitive function and mood."

Two of its authors work for a company that uses Lion's Mane. And the trial came out null anyway.

That makes the null result stronger, not weaker. Funding and affiliation generally push results in a favourable direction, so a null finding published by a team with a commercial interest in the ingredient is harder to explain away than a null finding from a neutral lab. If anyone was positioned to find an effect and motivated to report one, it was these authors, and they reported nothing.

Practical Context

Here is the arithmetic that most brands in this category will not show you.

MIND MELT contains Lion's Mane 30 mg per strip, alongside maitake 25 mg, cordyceps 25 mg and shiitake 20 mg.

So the position, stated plainly: MIND MELT does not deliver a dose that has been studied in a human trial, and Majestic X will not imply that it does. On top of that, no published trial has tested a four-mushroom combination at all, so the blend itself has no human research behind it.

Why say this out loud? Because the doses are printed on our label and the trial doses are published in peer-reviewed journals. Anyone can do the division in under a minute. We would rather be the ones who did it.

If you are shopping this category more broadly, the useful questions are: how many milligrams of the actual mushroom, which form or extract, and how does that compare to the 1.8 to 3 gram range used in the trials that reported anything at all?

And if you are considering Lion's Mane for a real cognitive concern, that belongs with a doctor. Cognitive symptoms deserve a diagnosis, not a supplement.

Limitations and What We Do Not Know

We do not know the effective dose of Lion's Mane in healthy adults, because it has not been established.

We do not know whether extract type matters, because no trial has compared them head to head.

We do not know the safety profile at any dose, because the largest trial in the set had 41 participants.

We do not know anything about multi-mushroom blends from human research, because none has been tested.

And we do not have a trial at 30 mg. Not a weak trial, not a mixed trial. None. That is the honest state of the evidence for the amount in our own product, and it is the reason this article exists in the form it does.